Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited

Healthcare

NYSE:TAK · New York Stock Exchange

Market Cap $50.27B Beta 0.09 P/E (TTM) 41.4
$15.91 +0.25%

+$0.04 today

52W Low $12.99High $18.90

Vol 3.76M · Avg 3.09M

EPS (TTM)$122.72
Div Yield3.94%
Drug Manufacturers - Specialty & Generic

Dividends

Measure the reliability of shareholder income

Look beyond the current yield by checking payout history, cash support, buybacks, and other ways management returns capital to owners.

Dividends

Dividend history, growth & yield

Dividends

Yield

3.94%

Annual Div/Share

$0.62

Payout Ratio

162.7%

Frequency

Semi-Annual

Shareholder Yield

766.71%

Next Ex-Date

Not announced

Next Payment

1Y Growth

+3.1%

3Y CAGR

-1.0%

5Y CAGR

-5.8%

Dividend Payments, Annual Total (TTM) & Yield

Analysis

The current indicated dividend yield is 3.94%, with TTM dividends of $0.62 per share. Three-year dividend growth is -1.0%, which helps show whether payouts are compounding or flattening. The payout ratio is 162.7%, so compare payout growth against earnings coverage. Payments are currently semi-annual.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

Dividend Yield (TTM)

618.70%

Buyback Yield (TTM)

107.22%

Debt Paydown (TTM)

0.00%

Total Yield (TTM)

725.92%

Analysis

Total TTM shareholder yield is 725.92% including 0.00% from debt paydown. The largest current contributor is dividends at 618.70%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.

Competitor Dividends

Peer payout, dividend, and buyback comparison

No competitor dividend data available.

Does TAK stock pay dividends?

Takeda Pharmaceutical Company Limited (TAK) currently pays a dividend. The indicated dividend per share is 0.62 USD and the dividend yield is 3.94%.

Is TAK's dividend covered?

The payout ratio is 162.7%, so compare that against earnings and free cash flow before relying on the dividend.

Explore More

Continue the stock analysis

Jump to another research area for this company.